Shennon Biotechnologies
Shennon Biotechnologies (ShennonBio) combines its TCELERATOR ultra-high-throughput single-cell interaction screening platform with AI models for target discovery (PINTRA), binder design (AFFINIS) and safety prediction (SERIS). It is building a pipeline of precision immunotherapies for cancer and plans to license programs and platform capabilities to partners. It raised a roughly $13M seed round led by DCVC in 2023 and a $12M financing in September 2026 from Future Ventures, NextGen and others. In 2026 it named Cyril Konto, M.D., as CEO, with founder Li Sun moving to President and CTO. It runs about 6,000 sq ft of lab space near UCSF Mission Bay.
Funding
Every round, secondary, debt facility or acquisition involving Shennon Biotechnologies that AI Lounge tracks, newest first. Latest: Venture round on Sep 14, 2026.
Timeline · 2
In the news
Members see every AI company on AI Lounge with revenue, funding, valuation and investors, searchable and sortable, free.
Create my free account →Log in